Pricing

Health Sciences Acquisitions Corp (IMVTU)

followers ·
Sector:
FINANCE
Industry:
GENERAL FINANCE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Peter Salzmann
Employees:
120
320 WEST 37TH STREET, NEW YORK, NY, 10018
917-580-3099

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available